scholarly journals Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.

1990 ◽  
Vol 34 (10) ◽  
pp. 1875-1879 ◽  
Author(s):  
S Dutka-Malen ◽  
R Leclercq ◽  
V Coutant ◽  
J Duval ◽  
P Courvalin
Antibiotics ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 915
Author(s):  
Robert E. Weber ◽  
Carola Fleige ◽  
Franziska Layer ◽  
Bernd Neumann ◽  
Michael Kresken ◽  
...  

Dalbavancin is a lipoglycopeptide antibiotic that shows potent activity against Gram-positive bacteria. It circumvents vanB-type glycopeptide resistance mechanisms; however, data on the in vitro activity of dalbavancin for Enterococcus faecium (E. faecium) are scarce, and thus, no breakpoints are provided. In recent years, there has been a continuing shift from vanA-type to vanB-type vancomycin-resistance in enterococci in Central Europe. Therefore, we aimed to investigate the in vitro activity of dalbavancin against different van-genotypes, with particular focus on vanB-type E. faecium. Dalbavancin susceptibility was determined for 25 van-negative, 50 vanA-positive, and 101 vanB-positive clinical E. faecium isolates (typed by cgMLST). Epidemiological Cut-Off Values (ECOFFs) were determined using ECOFFinder. For vanB-type E. faecium isolates, dalbavancin MICs were similar to those of vancomycin-susceptible isolates reaching values no higher than 0.125 mg/L. ECOFFs for van-negative and vanB-positive isolates were 0.5 mg/l and 0.25 mg/L respectively. In contrast, E. faecium possessing vanA predominantly showed dalbavancin MICs >8 mg/L, therefore preventing the determination of an ECOFF. We demonstrated the potent in vitro activity of dalbavancin against vancomycin-susceptible and vanB-type E. faecium. On the basis of the observed wildtype distribution, a dalbavancin MIC of 0.25 mg/L can be suggested as a tentative ECOFF for E. faecium.


2015 ◽  
Vol 53 (12) ◽  
pp. 3931-3934 ◽  
Author(s):  
Blake W. Buchan ◽  
Garrett C. Reymann ◽  
Paul A. Granato ◽  
Brenda R. Alkins ◽  
Patricia Jim ◽  
...  

The iC-GPC assay (iCubate, Huntsville, AL) provides a molecular option for the rapid, on-demand analysis of positive blood cultures. A preliminary evaluation of the iC-GPC assay using 203 clinical or seeded specimens demonstrated a sensitivity of 93.8% to 100% and a specificity of 98.0% to 100% for the identification of five Gram-positive bacterial species (Staphylococcus aureus,Staphylococcus epidermidis,Streptococcus pneumoniae,Enterococcus faecalis, andEnterococcus faecium) and three associated genetic resistance determinants (mecA,vanA, andvanB) in positive blood culture broths.


Author(s):  
Seon Young Kim ◽  
Yun Ji Hong ◽  
Sang Mee Hwang ◽  
Taek Soo Kim ◽  
Jae-Seok Kim ◽  
...  

AbstractThe Verigene Gram-Positive Blood Culture (BC-GP) nucleic acid assay (Nanosphere, Inc., Northbrook, IL, USA) is a newly developed microarray-based test with which 12 Gram-positive bacterial genes and three resistance determinants can be detected using blood culture broths. We evaluated the performance of this assay and investigated the signal characteristics of the microarray images.At the evaluation stage, we tested 80 blood cultures that were positive for various bacteria (68 bacteria covered and 12 not covered by the BC-GP panel) collected from the blood of 36 patients and 44 spiked samples. In instances where the automated system failed and errors were called, we manually inspected microarray images, measured the signal intensities of target spots, and reclassified the results.With the manual analysis of the microarray images of 14 samples for which error calls were reported, we could obtain correct identification results for 12 samples without the need for retesting, because strong signals in the target spots were clearly discriminable from background noise. With our interpretation strategy, we could obtain 97.1% sensitivity and 100% specificity for bacterial identification by using the BC-GP assay. The two unidentified bacteria were viridans group streptococci, which produced weaker target signals. During the application stage, among 25 consecutive samples positive for Gram-positive bacteria, we identified two specimens with error calls asWith help of the manual review of the microarray images, the BC-GP assay could successfully identify species and resistance markers for many clinically important Gram-positive bacteria.


2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
S. Sujatha ◽  
Ira Praharaj

Vancomycin-resistant enterococci (VRE) have emerged as important nosocomial pathogens in the past two decades all over the world and have seriously limited the choices available to clinicians for treating infections caused by these agents. Methicillin-resistantStaphylococcus aureus, perhaps the most notorious among the nosocomial pathogens, was till recently susceptible to vancomycin and the other glycopeptides. Emergence of vancomycin nonsusceptible strains ofS. aureushas led to a worrisome scenario where the options available for treating serious infections due to these organisms are very limited and not well evaluated. Vancomycin resistance in clinically significant isolates of coagulase-negative staphylococci is also on the rise in many setups. This paper aims to highlight the genetic basis of vancomycin resistance inEnterococcusspecies andS. aureus. It also focuses on important considerations in detection of vancomycin resistance in these gram-positive bacteria. The problem of glycopeptide resistance in clinical isolates of coagulase-negative staphylococci and the phenomenon of vancomycin tolerance seen in some strains ofStreptococcus pneumoniaehas also been discussed. Finally, therapeutic options available and being developed against these pathogens have also found a mention.


Sign in / Sign up

Export Citation Format

Share Document